Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

Peer Review reports

Original Submission
16 Jul 2020	Submitted	Original manuscript
21 Jul 2020	Reviewed	Reviewer Report
26 Jul 2020	Reviewed	Reviewer Report - Gerard G. Hanna
4 Aug 2020	Author responded	Author comments - Farastuk Bozorgmehr
Resubmission - Version 2
4 Aug 2020	Submitted	Manuscript version 2
Publishing
5 Aug 2020	Editorially accepted
26 Aug 2020	Article published	10.1186/s12885-020-07264-8

Back to article page